

MIGNONE ROBERTO

Form 4

May 11, 2018

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
MIGNONE ROBERTO

2. Issuer Name **and** Ticker or Trading  
Symbol  
TEVA PHARMACEUTICAL  
INDUSTRIES LTD [TEVA]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
C/O TEVA PHARMACEUTICAL  
INDUSTRIES LTD., 5 BASEL  
STREET

3. Date of Earliest Transaction  
(Month/Day/Year)  
05/09/2018

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

(Street)

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

PETACH TIKVA, L3 4951033

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------|
|                                       |                                         |                                                             |                                      | Code V Amount (A) or (D) Price                                          |                                                                                                                    |                                                                         |                                                                   |
| Ordinary<br>Shares <sup>(1)</sup>     | 05/09/2018                              |                                                             | P                                    | 500,000 A \$ 19.2063 <sup>(2)</sup>                                     | 1,250,000                                                                                                          | I                                                                       | [see<br>footnote]<br><sup>(3)</sup>                               |
| Ordinary<br>Shares <sup>(1)</sup>     | 05/10/2018                              |                                                             | P                                    | 250,000 A \$ 19.3188 <sup>(4)</sup>                                     | 1,500,000                                                                                                          | I                                                                       | [see<br>footnote]<br><sup>(3)</sup>                               |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form**

SEC 1474  
(9-02)

**displays a currently valid OMB control number.**

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and<br>Amount of<br>Underlying<br>Securities<br>(Instr. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number<br>of<br>Derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 10) |
|-----------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
|                                                     |                                                                    |                                         |                                                             | Code                                 | V (A) (D)                                                                                                          | Date<br>Exercisable                                            | Expiration<br>Date                                                        | Title                                               | Amount<br>or<br>Number<br>of<br>Shares                                                                                      |

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

MIGNONE ROBERTO  
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.  
5 BASEL STREET  
PETACH TIKVA, L3 4951033

X

## Signatures

/s/ Dov Bergwerk, as attorney-in-fact for Roberto  
Mignone

05/11/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

The price reported in Column 4 is a weighted average price. These Ordinary Shares were purchased in multiple transactions at prices ranging from \$18.99 to \$19.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of Ordinary Shares purchased at each separate price.

The 1,500,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Funds for purposes of Section 16, or for any other purpose.

## Edgar Filing: MIGNONE ROBERTO - Form 4

- The price reported in Column 4 is a weighted average price. These Ordinary Shares were purchased in multiple transactions at prices
- (4) ranging from \$19.2450 to \$19.3700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of Ordinary Shares purchased at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.